Literature DB >> 12844326

Therapeutic drug monitoring of antiarrhythmic drugs.

Gesche Jürgens1, Niels A Graudal, Jens P Kampmann.   

Abstract

Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug monitoring, as they show highly variable plasma concentration profiles at a given dose and a direct concentration-effect relationship. Therapeutic ranges for antiarrhythmic drugs are, however, often very poorly defined. Effective drug concentrations are based on small studies or studies not designed to establish a therapeutic range, with varying dosage regimens and unstandardised sampling procedures. There are large numbers of nonresponders and considerable overlap between therapeutic and toxic concentrations. Furthermore, no study has ever shown that therapeutic drug monitoring makes a significant difference in clinical outcome. Therapeutic concentration ranges for antiarrhythmic drugs as they exist today can give an overall impression about the drug concentrations required in the majority of patients. They may also be helpful for dosage adjustment in patients with renal or hepatic failure or in patients with possible toxicological or compliance problems. Their use in optimising individual antiarrhythmic therapy, however, is very limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844326     DOI: 10.2165/00003088-200342070-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  225 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

2.  The convulsant potency of lidocaine and its N-dealkylated metabolites.

Authors:  J Blumer; J M Strong; A J Atkinson
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

3.  Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment.

Authors:  M Sami; D C Harrison; H Kraemer; N Houston; C Shimasaki; R F DeBusk
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

4.  Mexiletine for ventricular arrhythmias.

Authors:  P J Podrid; B Lown
Journal:  Am J Cardiol       Date:  1981-04       Impact factor: 2.778

5.  Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias.

Authors:  J P diMarco; T D Sellers; B B Lerman; M L Greenberg; R M Berne; L Belardinelli
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

6.  Disposition of tablet and capsule formulations of digoxin in the elderly.

Authors:  J Hui; Y M Wang; A Chandrasekaran; D R Geraets; J H Caldwell; L W Robertson; R H Reuning
Journal:  Pharmacotherapy       Date:  1994 Sep-Oct       Impact factor: 4.705

7.  Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers.

Authors:  J Bonde; N M Jensen; L E Pedersen; N A Graudal; H R Angelo; J P Kampmann
Journal:  Pharmacol Toxicol       Date:  1988-05

8.  Amiodarone: pharmacology and antiarrhythmic and adverse effects.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; R A Giebel
Journal:  Pharmacotherapy       Date:  1985 Nov-Dec       Impact factor: 4.705

9.  Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.

Authors:  D M Roden; S B Reele; S B Higgins; G R Wilkinson; R F Smith; J A Oates; R L Woosley
Journal:  Am J Cardiol       Date:  1980-09       Impact factor: 2.778

10.  Electrophysiological actions of mexiletine on isolated rabbit atria and canine ventricular muscle and purkinje fibres.

Authors:  I Yamaguchi; B N Singh; W J Mandel
Journal:  Cardiovasc Res       Date:  1979-05       Impact factor: 10.787

View more
  8 in total

1.  Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring.

Authors:  Kosuke Doki; Yuki Shirayama; Yukio Sekiguchi; Kazutaka Aonuma; Yukinao Kohda; Masato Homma
Journal:  Eur J Clin Pharmacol       Date:  2018-08-16       Impact factor: 2.953

2.  Complications of catheter ablation for ventricular tachycardia.

Authors:  Aishwarya Pastapur; Daniel McBride; Amrish Deshmukh; Stefanie Driesenga; Michael Ghannam; Frank Bogun; Jackson J Liang
Journal:  J Interv Card Electrophysiol       Date:  2022-09-02       Impact factor: 1.759

3.  5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability.

Authors:  Marie Louise Navez; Christopher Monella; Irmgard Bösl; Daniela Sommer; Claire Delorme
Journal:  Pain Ther       Date:  2015-04-21

4.  Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients.

Authors:  Roberta Bursi; Chiara Piana; Joachim Grevel; Dymphy Huntjens; Irmgard Boesl
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

5.  Increased serum amiodarone concentration in hypertriglyceridemic patients: Effects of drug distribution to serum lipoproteins.

Authors:  Naoaki Hashimoto; Kosuke Doki; Satoru Kawano; Kazutaka Aonuma; Masaki Ieda; Masato Homma
Journal:  Clin Transl Sci       Date:  2021-11-25       Impact factor: 4.689

6.  Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster.

Authors:  Gerardo Correa-Illanes; Wilfredo Calderón; Ricardo Roa; José Luis Piñeros; Jacqueline Dote; David Medina
Journal:  Local Reg Anesth       Date:  2010-08-20

7.  Analysis of stochastic fluctuations in responsiveness is a critical step toward personalized anesthesia.

Authors:  Andrew R McKinstry-Wu; Andrzej Z Wasilczuk; Benjamin A Harrison; Victoria M Bedell; Mathangi J Sridharan; Jayce J Breig; Michael Pack; Max B Kelz; Alexander Proekt
Journal:  Elife       Date:  2019-12-03       Impact factor: 8.140

8.  Direct analysis in real time-mass spectrometry for rapid quantification of five anti-arrhythmic drugs in human serum: application to therapeutic drug monitoring.

Authors:  Yuzhou Gui; Youli Lu; Shuijun Li; Mengqi Zhang; Xiaokun Duan; Charles C Liu; Jingying Jia; Gangyi Liu
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.